The Proportion of Radiation Pneumonitis among Lung Cancer Patients in Persahabatan Hospital

Dini Rizkie Wijayanti, Jamal Zaini, Achmad Hudoyo, Aziza Ghanie, Westi ATW

Abstract


Background : Radiation-induced pulmonary toxicity occurs in patients with lung cancer who received irradiation. The objective of this study was to determine the proportion of radiation pneumonitis among lung cancer patients that were exposed to radiation treatment in Persahabatan Hospital. There is no data about proportion of radiation pneumonitis in Indonesia.

Methods: This was a retrospective study conducted in Persahabatan Hospital during June 2013– July 2015 using the medical record of lung-cancer patients who received irradiation.

Results: 33 lung-cancer patients fulfilled the inclusion criteria. Most of them were male (66.7%), in age ≥ 51 years (63.6%), had a smoking history (75.8%) with moderate Brinkman Index (60%), were given irradiation doses of 3,000–4,000 (60.6%) with irradiation fractions of 10–19 (60.6%), had no history of chemotherapy (54.5%), and were diagnosed with adenocarcinoma (66.7%) and stage-IV cancer (84.84%). The proportion of radiation pneumonitis based on chest X-ray (CXR) was 39.4%; which consisted of hazy ground-glass opacities, hazy ground-glass opacities, and fibrosis, and only fibrosis. There were significant differences in age, radiation doses, and history of chemotherapy with the proportion of radiation pneumonitis (p < .05).

Conclusion: The proportion of radiation pneumonitis based on CXR was 39.4%. There were significant differences in age, radiation doses, and history of chemotherapy with the proportion of radiation pneumonitis.

 


Keywords


lung cancer, radiation pneumonitis, radiation

References


Sause WT, Gregor A. Treatment of NSCLC: radiotherapy. In:Hansen HH, editor. Textbook of lung cancer.London:Martin Dunitz;2000.p.201-7.

Fraser RA. Radiation pneumonitis and fibrosis. In: Johkoh T, Muller NL, Fraser RA, Lee KS, editors. Diseases of the lung:radiologic and pathologic correlations 1sted. Philadelphia:LippincottWilliam&Wilkins;2003.p.230-7.

Ivan R, Soren M. A literature-based meta-analysis of clinical risk factors for the development of radiation-induced pneumonitis. Acta Oncologica. 2012;8:976-9.

Youngkyong K, Seong EH, Moonkyoo K, Jinhyun C. Predictive factors for radiation pneumonitis in lung cancer treated with helical tomotherapy. J Kor Can Assoc. 2013;45:295-302.

Kharofa J, Gore E. Symptomatic radiation pneumonitis in elderly patients receiving thoracic irradiation. Clin Lung Cancer. 2013;14:283-7.

Baker R, Han G, Sarangkasiri S, Demarco M, Turke C. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy of the lung. Int J Radiat Oncol Biol Phys. 2013;85:190-5.

Weytjens R, Erven K, Ruysscher D. Radiation pneumonitis: occurrence, prediction, prevention, and treatment R. Belg J Med Oncol. 2013;7(4):105-10.

Takeyuki M, Satoshi T, Kazushige.Risk factors for severe radiation pneumonitis in lung cancer.Jpn J ClinOncol. 1999;29:192-7.

Joanne N, Clinton M, Sanjeev S, John P, Frank K, David P, et al. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the research patient registry. Rad Oncol. 2015;10:113-7.

William J, Rubin P, Sandra MD, Dombrowki J. Supportive care in thoracic oncology: chemoradiation pneumonitis and esophagitis. In:Movsas B, Langer CJ, Goldberg M, editors. Controversies in lung cancer 3rded. New York:Marcel Dekker;2001.p.389-405.

Federica MD, Luigi M, Glusi IF. Portrait of inflammatory response to ionizing radiation treatment. Journal of Inflammation. 2015;10:12-4.

Erasmus JJ, Kara B, Munden R. Iatrogenic lung disease and trauma. In: Mulller, Nestor L, editors. High yield imaging:chest 1st ed. Philadelphia:Saunders;2009.p.1225-38.


Full Text: PDF

DOI: 10.33371/ijoc.v14i2.701

Article Metrics

Abstract view : 87 times
PDF - 35 times

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.